FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
MAP Pharmaceuticals Reports Positive Phase 2 Results for its Pediatric Asthma Drug Candidate
March 15th, 2007
MAP Pharmaceuticals, Inc. announced that its Unit Dose Budesonide (UDB) drug candidate met its primary efficacy endpoints in a Phase 2 clinical trial. UDB is a proprietary nebulized formulation of budesonide for treatment of pediatric asthma. The multicenter, randomized, double-blind, placebo-controlled U.S. based study aimed to assess the efficacy of UDB versus placebo at two doses in patients as young as 12-months old. The study met its primary efficacy endpoints. The high dose evaluated in the study was equivalent to the lowest dose available of the currently marketed nebulized budesonide product. The primary endpoints for the study were asthma...
Source: FDA Law Weekly (2007-03-15)
|
